Generic Central Nervous System Drugs Market 2025–2029: Strategic Opportunities and Growth Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the generic central nervous system drugs market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Generic Central Nervous System Drugs Market Now And By 2029?

The xerostomia therapeutics market has demonstrated consistent expansion in recent years. It is anticipated to increase from $2.14 billion in 2024 to $2.24 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.7%. The historical growth trajectory can be attributed to several factors, including the increasing incidences of xerostomia in the geriatric population, ongoing research and development efforts for efficient xerostomia products, growing awareness about xerostomia-related products, an increase in various medical conditions, and the rising prevalence of chronic diseases.

The xerostomia therapeutics market size is expected to experience steady growth in the coming years, projected to reach $2.69 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 4.7%. This expansion during the forecast period is attributable to several factors, including the easy availability of cost-effective medications in the market, an increased prevalence of oral health conditions, rising awareness among healthcare practitioners, various government initiatives, and a general increase in medication usage. Key trends anticipated in the forecast period involve artificial saliva and saliva substitutes, continuous technological advancements and product innovations, the development of personalized medicine and targeted therapies, the growth of telehealth and remote monitoring, and an increasing prominence of non-invasive therapies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Which Long-Term Drivers Are Expected To Sustain The Generic Central Nervous System Drugs Market?

The growing utilization of chemotherapy in managing cancer is anticipated to fuel the expansion of the xerostomia therapeutics market in the future. In the context of cancer care, chemotherapy involves administering potent drugs designed to eliminate or impede the proliferation of malignant cells. The increasing widespread acceptance of chemotherapy for cancer stems primarily from its efficacy in precisely targeting and eliminating cancerous cells across the body. Xerostomia treatments encompass medications or oral rinses that stimulate saliva, thereby boosting saliva generation and improving taste, which facilitates easier eating and proper nutritional intake for patients. For example, as reported by the US-based government entity, the National Cancer Institute, in January 2022, an estimated 18.1 million cancer survivors resided in the United States, representing 5.4% of the total population. Projections indicate that by 2032, the global number of cancer survivors will reach 22.5 million, marking a 24.4% rise from the current figures. Consequently, the expanding use of chemotherapy in cancer therapy is significantly contributing to the advancement of the xerostomia therapeutics market.

How Is The Generic Central Nervous System Drugs Market Classified By Different Segments?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Current And Upcoming Trends Are Shaping The Generic Central Nervous System Drugs Market?

Leading companies within the xerostomia therapeutics market are innovating patient-friendly, non-invasive solutions, such as oral sprays, to meet the demand for convenient and effective dry mouth management. These oral sprays enable targeted application to the affected areas of the mouth, supplying essential moisture and lubrication precisely where required. For instance, in July 2023, K Pharmaceuticals, an India-based pharmaceutical firm, introduced Aquoral, a clinically validated oral spray aimed at alleviating dry mouth, also known as xerostomia. This condition can stem from various causes, including medications and illnesses, potentially leading to discomfort, challenges with chewing and swallowing, and other oral health issues. Aquoral provides sustained relief for up to six hours by establishing a durable protective layer over the oral cavity, which reduces moisture evaporation and improves comfort. Unlike conventional water-based treatments that demand frequent reapplication, Aquoral utilizes patented Oxidized Glycerol Triesters (OGT), a plant-derived, lipid-based technology offering superior protection.

Who Are The Primary Market Leaders In The Generic Central Nervous System Drugs Market?

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Generic Central Nervous System Drugs Market?

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Browse Through More Reports Similar to the Global Generic Central Nervous System Drugs Market 2025, By The Business Research Company

Peptide Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795